Empagliflozin inhibits proximal tubule NHE3 activity, preserves GFR and restores euvolemia in nondiabetic rats with induced heart failure
Authors:
- Flavio Araujo Borges-JuniorFBFlavio Araujo Borges-Junior
- Danúbia Silva dos SantosDSDanúbia Silva dos Santos
- Acaris BenettiABAcaris Benetti
- Renato Oliveira CrajoinasRCRenato Oliveira Crajoinas
- Ednei L. AntonioEAEdnei L. Antonio
- Leonardo JensenLJLeonardo Jensen
- Bruno CaramelliBCBruno Caramelli
- Gerhard MalnicGMGerhard Malnic
- Paulo J. TucciPTPaulo J. Tucci
- Adriana C. GirardiAGAdriana C. Girardi
Preprint
Abstract
Background: Sodium-glucose cotransporter type 2 (SGLT2) inhibitors reduce the risk of heart failure (HF) mortality and morbidity, regardless of the presence or absence of diabetes, but the mechanisms underlying this benefit remain unclear. We tested the hypothesis that the SGLT2 inhibitor empagliflozin inhibits proximal tubule (PT) Na + /H + exchanger isoform 3 (NHE3) activity and improves renal salt and water handling in nondiabetic rats with HF. Methods and Results: Male Wistar rats were subjected to myocardial infarction or sham operation. After four weeks, rats that developed HF and sham rats were treated with empagliflozin (EMPA) or untreated for an additional four weeks. EMPA-treated HF rats displayed lower levels of serum brain natriuretic peptide (BNP) and lower right ventricle and lung weight to tibia length than untreated HF rats. Upon saline challenge, the diuretic and natriuretic responses of EMPA-treated HF rats were similar to those of sham rats and were higher than those of untreated HF rats. Additionally, EMPA treatment normalized the glomerular filtration rate and proteinuria in HF rats. PT NHE3 activity was higher in HF rats than in sham rats, whereas treatment with EMPA markedly reduced NHE3 activity. Unexpectedly, SGLT2 function and protein and mRNA abundance were upregulated in the PT of HF rats. Conclusion: Collectively, our data show that the prevention of HF progression by empagliflozin is associated with inhibition of PT NHE3 activity and restoration of euvolemia. Moreover, we propose that the dysregulation of PT SGLT2 may be involved in the pathophysiology of nondiabetic HF. SIGNIFICANCE STATEMENT: SGLT2 inhibitors represent a class of drugs that were originally developed for improving glycemic control. Cardiovascular outcome trials that were designed to evaluate cardiovascular safety yielded unexpected and unprecedented evidence of the cardiorenal benefits of SGLT2 inhibitor. Many hypotheses have been proposed to explain the mechanisms underlying these effects. Our study demonstrates that SGLT2 inhibition restores extracellular volume homeostasis in nondiabetic heart failure (HF) rats by preserving GFR and inhibiting proximal tubule NHE3-mediated sodium reabsorption. The attenuation of kidney dysfunction may constitute an essential mechanism by which SGLT2 inhibitors attenuate HF development and progression either in the presence or absence of diabetes.Keywords
All Related Versions
- Published version: Journal of the American Society of Nephrology, 32 (7), 1616.
This publication has 34 references indexed in Scilit:
- Renal nerve stimulation leads to the activation of the Na+/H+exchanger isoform 3 via angiotensin II type I receptorAmerican Journal of Physiology-Renal Physiology, 2015
- Novel Renal Biomarkers to Assess Cardiorenal SyndromeCurrent Heart Failure Reports, 2014
- Functional Role of Glucose Metabolism, Osmotic Stress, and Sodium-Glucose Cotransporter Isoform-Mediated Transport on Na+/H+ Exchanger Isoform 3 Activity in the Renal Proximal TubuleJournal of the American Society of Nephrology, 2014
- Deciphering the mechanisms of the Na+/H+ exchanger-3 regulation in organ dysfunctionAmerican Journal of Physiology-Cell Physiology, 2012
- Increased NHE3 abundance and transport activity in renal proximal tubule of rats with heart failureAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2012
- SGLT2 Mediates Glucose Reabsorption in the Early Proximal TubuleJournal of the American Society of Nephrology, 2011
- Posttranslational mechanisms associated with reduced NHE3 activity in adult vs. young prehypertensive SHRAmerican Journal of Physiology-Renal Physiology, 2010
- Use of phospho-specific antibodies to determine the phosphorylation of endogenous Na+/H+ exchanger NHE3 at PKA consensus sitesAmerican Journal of Physiology-Renal Physiology, 2005
- Angiotensin II-dependent increased expression of Na+-glucose cotransporter in hypertensionAmerican Journal of Physiology-Renal Physiology, 2004
- Molecular mechanisms of glucose action on angiotensinogen gene expression in rat proximal tubular cellsKidney International, 1999